- 专利标题： Substituted benzimidazole derivative as a modulator of TNF activity
-
申请号： US16349734申请日： 2017-12-08
-
公开(公告)号： US10669263B2公开(公告)日： 2020-06-02
- 发明人: Jag Paul Heer
- 申请人： UCB Biopharma SRL
- 申请人地址： BE Brussels
- 专利权人： UCB Biopharma SRL
- 当前专利权人： UCB Biopharma SRL
- 当前专利权人地址： BE Brussels
- 代理机构： McDonnell Boehnen Hulbert & Berghoff LLP
- 优先权： com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@d467382
- 国际申请： PCT/EP2017/082092 WO 20171208
- 国际公布： WO2018/104534 WO 20180614
- 主分类号： A61K31/506
- IPC分类号： A61K31/506 ; A61K31/4184 ; C07D403/04 ; A61P37/00 ; A61P25/28 ; A61P3/00 ; A61P9/00 ; A61P37/08 ; A61P29/00 ; A61P35/00
摘要：
2-(5-{1-[2-(Difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
公开/授权文献
信息查询
IPC分类:
